11.92

0.93% 0.11

Roivant Sciences Ltd (ROIV)

Overview News Price History Option Chain Financials Why ROIV Down? Discussions Forecast

Roivant Sciences Ltd stock is traded at $11.92, with a volume of 4.90M. It is up +0.93% in the last 24 hours and up +3.65% over the past month. Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Previous Close:

$11.81

Open:

$11.85

24h Volume:

4.90M

Relative Volume:

0.87

Market Cap:

$8.14B

Revenue:

$125.68M

Net Income/Loss:

$4.81B

P/E Ratio:

2.1097

EPS:

5.65

Net Cash Flow:

$-781.21M

1W Performance:

+0.59%

1M Performance:

+3.65%

6M Performance:

+11.61%

1Y Performance:

+2.05%

1-Day Range:

$11.82

$12.03

1-Week Range:

$11.54

$12.03

52-Week Range:

$8.73

$13.05

Roivant Sciences Ltd Stock (ROIV) Company Profile

Name

Roivant Sciences Ltd

Sector

Healthcare (1157)

Industry

Biotechnology (645)

Phone

441-295-5950

Address

7TH FLOOR, 50 BROADWAY, LONDON

Employee

750

Twitter

Next Earnings Date

2025-02-10

Latest SEC Filings

ROIV's Discussions on Twitter

Compare ROIV with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ROIV Roivant Sciences Ltd	11.92	8.06B	125.68M	4.81B	-781.21M	5.65
VRTX Vertex Pharmaceuticals Inc	395.12	99.96B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	589.48	60.83B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	454.38	59.89B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	660.00	40.47B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	313.67	37.96B	3.81B	-644.79M	-669.77M	-6.24

Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-10-25	Resumed	Goldman	Buy
Feb-15-24	Initiated	Wolfe Research	Outperform
Jan-05-24	Initiated	Piper Sandler	Overweight
Dec-12-23	Initiated	Deutsche Bank	Buy
Oct-17-23	Initiated	Guggenheim	Buy
Jun-08-23	Initiated	BofA Securities	Neutral
Oct-27-22	Initiated	JP Morgan	Overweight
May-23-22	Initiated	SVB Leerink	Outperform
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight
Dec-15-21	Initiated	Goldman	Buy
Nov-08-21	Initiated	H.C. Wainwright	Buy
Oct-28-21	Initiated	Citigroup	Buy
Oct-26-21	Initiated	Cowen	Outperform
Oct-26-21	Initiated	Jefferies	Buy
Oct-26-21	Initiated	Truist	Buy

View All

Roivant Sciences Ltd Stock (ROIV) Latest News

Aug 20, 2025

Will Breakout in Roivant Sciences Ltd. Sustain Through Next Week2025 Buyback Activity & Free Community Consensus Stock Picks - thegnnews.com

Aug 20, 2025

Aug 18, 2025

Machine Learning Models Forecast Roivant Sciences Ltd. Uptick2025 Short Interest & Weekly High Conviction Trade Ideas - newsimpact.co.kr

Aug 18, 2025

Roivant plans $500M new share repurchase as brepocitinib data readout nears - MSN

Aug 18, 2025

Is It Too Late to Sell Roivant Sciences Ltd.2025 Risk Factors & Free Risk Controlled Daily Trade Plans - newsimpact.co.kr

Aug 18, 2025

Price Consolidation Hints at Upcoming Move in Roivant Sciences Ltd.Earnings Growth Report & Safe Swing Trade Setups - 선데이타임즈

Aug 18, 2025

Aug 17, 2025

Roivant’s High-Stakes Pipeline Bets On Biotech Breakthroughs - Finimize

Aug 17, 2025

Aug 15, 2025

Press Release: Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update - 富途牛牛

Aug 15, 2025

Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack (NASDAQ:ROIV) - Seeking Alpha

Aug 15, 2025

Aug 13, 2025

Roivant Sciences Ltd. Approaches Psychological Resistance Level2025 Big Picture & Weekly Market Pulse Alerts - 선데이타임즈

Aug 13, 2025

Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Just Slashed This Year's Revenue Estimates By 17% - 富途牛牛

Aug 13, 2025

Roivant Sciences’ (ROIV) Aggressive Buybacks Amid Losses: Commitment to Shareholders or Growth Uncertainty? - simplywall.st

Aug 13, 2025

Aug 12, 2025

Roivant Sciences shares rise 2.91% intraday after announcing a $500 million share repurchase program. - AInvest

Aug 12, 2025

Chairman on Gubra CEO change: Henrik Blou wants to try something different - medwatch.com

Aug 12, 2025

Leerink Partners raises Roivant Sciences stock price target to $18 on lower share count By Investing.com - Investing.com South Africa

Aug 12, 2025

Leerink Partners raises Roivant Sciences stock price target to $18 on lower share count - Investing.com India

Aug 12, 2025

Roivant Sciences Q1 2025 Earnings Call Highlights: Strong Cash Position and Share Repurchase Amidst Legal and Market Challenges - AInvest

Aug 12, 2025